Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Coherus Biosciences, Inc. (NasdaqGM:CHRS) stands at -0.356668. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for Coherus Biosciences, Inc. (NasdaqGM:CHRS) is . Further, the Earnings to Price yield of Coherus Biosciences, Inc. NasdaqGM:CHRS is -0.365444. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance.

**Quant Signals – Value Composite, C- Score, MF Rank, M-Score, ERP5**

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Coherus Biosciences, Inc. (NasdaqGM:CHRS) is 99. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Coherus Biosciences, Inc. (NasdaqGM:CHRS) is 100.

Coherus Biosciences, Inc. (NasdaqGM:CHRS) currently has a Montier C-score of 2.00000. This indicator was developed by James Montier in an attempt to identify firms that were altering financial numbers in order to appear better on paper. The score ranges from zero to six where a 0 would indicate no evidence of book cooking, and a 6 would indicate a high likelihood of something amiss. A C-score of -1 would indicate that there is not enough information available to calculate the score. Montier used six inputs in the calculation. These inputs included a growing difference between net income and cash flow from operations, increasing receivable days, growing day’s sales of inventory, increasing other current assets, decrease in depreciation relative to gross property plant and equipment, and high total asset growth.

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Coherus Biosciences, Inc. (NasdaqGM:CHRS) is 18389. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

Coherus Biosciences, Inc. (NasdaqGM:CHRS) has an M-score Beneish of -25.724587. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

The last signal we’ll look at is the ERP5 Rank. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Coherus Biosciences, Inc. (NasdaqGM:CHRS) is 18417. The lower the ERP5 rank, the more undervalued a company is thought to be.

**Volatility/PI**

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Coherus Biosciences, Inc. (NasdaqGM:CHRS) is 67.155600. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Coherus Biosciences, Inc. (NasdaqGM:CHRS) is 73.040700. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 67.244300.

We can now take a quick look at some historical stock price index data. Coherus Biosciences, Inc. (NasdaqGM:CHRS) presently has a 10 month price index of 0.50408. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 0.44665, the 24 month is 0.67560, and the 36 month is 0.62405. Narrowing in a bit closer, the 5 month price index is 0.99597, the 3 month is 0.92164, and the 1 month is currently 1.46154.

**ROIC**

The Return on Invested Capital (aka ROIC) for Coherus Biosciences, Inc. (NasdaqGM:CHRS) is -5.552586. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. It tells investors how well a company is turning their capital into profits. The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital. The employed capital is calculated by subrating current liabilities from total assets. Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years. The ROIC Quality of Coherus Biosciences, Inc. (NasdaqGM:CHRS) is . This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC. The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets). The ROIC 5 year average of Coherus Biosciences, Inc. (NasdaqGM:CHRS) is .

Investors looking to potentially add any security to their portfolio should do all necessary research before making any investment decision.

**Fatal error**: Call to undefined function printFooterForm() in

**/home4/mando123/public_html/collinscourier.com/wp-content/themes/alpha/single.php**on line

**57**